The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

Anastasia Lanzi, F. A. Sinicrope, A. B. Benson, Jérôme Galon

Research output: Contribution to journalReview articlepeer-review


The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.

Original languageEnglish (US)
Article number1796003
Issue number1
StatePublished - Jan 1 2020


  • Immunoscore
  • cancer classification
  • immunity
  • phase 3 trial
  • prognosis
  • tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions'. Together they form a unique fingerprint.

Cite this